| GNFT Stock | | | USD 3.63 0.02 0.55% |
Chairman
Mr. JeanFrancois Mouney has served as Chairman of the Management Board and Chief Executive Officer of Genfit SA since 2008. Prior to this, he was Chairman of the Management Board of the Company between September 15, 1999 and 2008. He holds a Business Degree from the Paris Business School, and a degree in economics from the Universite Catholique de Lille. From 1979, he has created, managed and developed several companies specialised in high performance materials and in particular in the aeronautical industry. In 1992, he founded MM, a consultancy firm specialised in healthcare economy. He was responsible for carrying out a public feasibility study for an economic development agency in biologyhealthcare in the NordPasdeCalais region, and was appointed Managing Director of the agency when it was launched in 1995. actively involved from 1997 in the Companys incubation, he is cofounder of GENFIT, created in 1999. Chairman of the Management Board since that date, he received, in 2003 and again in 2004, the Entrepreneur of the Year award, organized internationally by Ernst Young, in the New Technology category. He is also Founder and Board Member of Naturalpha, a company created in 2001 specialised in Nutrition Research and Development and in clinical studies he is VicePresident of the research hub Nutrition, Health and Longevity since 2008.
| Age | 70 |
| Tenure | 17 years |
| Address | Parc EurasantE, Loos, France, 59120 |
| Phone | 33 3 20 16 40 00 |
| Web | https://www.genfit.com |
Mouney is Advisor of Banque de France since 2008.
Genfit Management Efficiency
The company has return on total asset
(ROA) of
0.0651 % which means that it generated a profit of $0.0651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
0.2591 %, meaning that it created $0.2591 on every $100 dollars invested by stockholders. Genfit's management efficiency ratios could be used to measure how well Genfit manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.28 in 2025.
Return On Capital Employed is likely to drop to -0.24 in 2025.
Total Current Liabilities is likely to drop to about 24.2
M in 2025.
Liabilities And Stockholders Equity is likely to drop to about 135.4
M in 2025
Genfit currently holds 70.18
M in liabilities with Debt to Equity
(D/E) ratio of 0.68, which is about average as compared to similar companies. Genfit has a current ratio of 6.2, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Genfit's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France. Genfit SA operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 134 people. Genfit (GNFT) is traded on NASDAQ Exchange in USA. It is located in Parc EurasantE, Loos, France, 59120 and employs 169 people. Genfit is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Genfit Leadership Team
Elected by the shareholders, the Genfit's board of directors comprises two types of representatives: Genfit inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genfit. The board's role is to monitor Genfit's management team and ensure that shareholders' interests are well served. Genfit's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genfit's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefanie JD, Chief Affairs | |
| Pascal Caisey, Chief Officer | |
| Sakina SayahJeanne, Executive Science | |
| Dean Hum, COO, Chief Scientific Officer, Member of the Management Board | |
| Thomas Baetz, Chief Officer | |
| Pr Staels, CoFounder Board | |
| JeanChristophe Marcoux, Chief Officer | |
| Meriam Kabbaj, Chief Officer | |
| Pascal Prigent, Chief Officer | |
| Laurent Lannoo, Corporate Affairs | |
| JeanFrancois Mouney, Chairman of the Management Board, CEO | |
| John Brozek, Executive Technology | |
| Stefanie Magner, Chief Affairs | |
| Emilie Desodt, Executive Resources | |
Genfit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genfit a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Genfit Stock Analysis
When running Genfit's price analysis, check to
measure Genfit's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit is operating at the current time. Most of Genfit's value examination focuses on studying past and present price action to
predict the probability of Genfit's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit's price. Additionally, you may evaluate how the addition of Genfit to your portfolios can decrease your overall portfolio volatility.